Both are long-acting incretin-pathway peptides, but tirzepatide adds GIP-receptor activity on top of GLP-1, and in head-to-head research it consistently produces larger glycaemic and weight effects than semaglutide.
Side-by-side comparison
| Property | Tirzepatide | Semaglutide |
|---|---|---|
| Targets | GLP-1, GIP | GLP-1 |
| Class | Dual agonist | Mono agonist |
| Half-life (research) | ~5 days | ~7 days |
| Sequence length | 39 aa | 31 aa |
| Albumin binding | C20 fatty-diacid | C18 fatty-diacid |
| Research stage | Approved | Approved |
| Head-to-head weight effect | Larger | Smaller |
| Head-to-head HbA1c effect | Larger | Smaller |
When researchers choose Tirzepatide
Tirzepatide is typically selected when the research question targets its specific mechanism or when comparative data against Semaglutide is the goal. ISO 17025 batch certificates are included with every shipment.
When researchers choose Semaglutide
Semaglutide is typically selected when the research question targets its specific mechanism. Both compounds undergo the same HPLC and mass-spec verification.
Reconstitution and dosing
Both peptides reconstitute identically with bacteriostatic water. See the reconstitution guide for sterile technique and the dosage guide for concentration maths.
FAQ: Tirzepatide vs Semaglutide
Does tirzepatide replace semaglutide in research?
It depends on the research question. Semaglutide remains the reference GLP-1 mono-agonist; tirzepatide is the reference for dual GLP-1 + GIP work.
Are reconstitution protocols the same?
Reconstitution technique is the same; the dose volume differs based on vial strength and study concentration.
Do both require cold storage after reconstitution?
Yes — both store at 2–8 °C after reconstitution.